Abstract: SA-PO0778
Glomerular Disease Registry and Biobank: Baseline and Follow-Up Results
Session Information
- Glomerular Research: Design, Registries, Surveys, and Epidemiology
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Kotwal, Sradha S., The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia
- Jeyaruban, Andrew Sujeevan, Royal North Shore Hospital, Sydney, New South Wales, Australia
- Bose, Bhadran, Nepean Hospital, Penrith, New South Wales, Australia
- Lee, Vincent W.S., The University of Sydney Westmead Applied Research Centre, Westmead, New South Wales, Australia
- Jardine, Meg, NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
- Mallawaarachchi, Amali, Garvan Institute of Medical Research, University of NSW, Sydney, New South Wales, Australia
- Ritchie, Angus G., Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
- Wong, Muh Geot, Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
- Makris, Angela, Liverpool Hospital, University of NSW, Sydney, New South Wales, Australia
- Badve, Sunil, St George Hospital, UNSW, Sydney, New South Wales, Australia
- Siriwardana, Amanda, Royal North Shore Hospital, Sydney, New South Wales, Australia
- Yong, Kenneth, Department of Nephrology, Prince of Wales Hospital, Sydney, New South Wales, Australia
- Perkovic, Vlado, The George Institute for Global Health, UNSW, Sydney, New South Wales, Australia
Background
Glomerular diseases (GD) are rare but carry substantial morbidity. Australian data on GD burden is limited. The glomerular diseases registry and biobank (GRIT) was established to address this gap. Here we describe the patient characteristics, treatment patterns and kidney function trajectory of participants in the GRIT registry.
Methods
GRIT is a prospective registry of adults with biopsy-proven GD at 7 tertiary referral centers in Sydney, Australia. Patients were consented for inclusion at time of biopsy and baseline data collected from medical records. Annual follow up was conducted through medical records using routine data during clinical follow up. Data includes demographics, diagnoses, kidney outcomes and medications.
Results
There were 230 patients enrolled between December 2018 and December 2024 with 118 participants also having bio banked samples. The median age of the participants was 49 years (IQR:39-63) and 39%(n=89) of the participants were female. The median baseline eGFR was 64mL/min/1.73m2 (IQR:38-90) with median urine albumin/creatinine of 188.05mg/mmol (IQR:54.5-398.8). The median time, from time of biopsy to entry was 13.5days (IQR:0-148). The most common diagnosis was Immunoglobulin A nephropathy (37.8%), followed by membranous nephropathy (17.4%). At baseline, 30.4% or participants were on corticosteroids, 8.7% had received cyclophosphamide (n=20, 8.7%). The most common immunosuppressants used at 3 months were corticosteroids (n=55,23.9%) followed by Tacrolimus (n=21,9.1%) and mycophenolate (n=18,7.8%). Over a median follow up of 3 years (IQR:1.8-4.3), the median eGFR decline was 2.1mL/min/1.73m2/year (IQR:0.5-4.9). The highest eGFR decline was 4.9 mL/min/1.73m2/year (IQR:1.7-48.5) in participants with membranous nephropathy. There were 130(56.5%) participants treated with angiotensin converting enzyme inhibitors/angiotensin receptor blocker, which increased to 161(70%) at 3 month follow up.
Conclusion
GRIT provides valuable real-world data on Australian patients with GD. Their rapid eGFR decline highlights the need for targeted treatments to slow the progression of disease. The biobank samples will facilitate future research and grow capacity in personalized medicine approaches to glomerular disease in Australia.
Funding
- Government Support – Non-U.S.